Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related deaths and is associated with a poor prognosis. The majority of these cancers are detected at a late stage, contributing to the bad prognosis. This underscores the need for novel, enhanced early detection strategies to improve the outcomes. While population-based screening is not recommended due to the relatively low incidence of PDAC, surveillance is recommended for individuals at high risk for PDAC due to their increased incidence of the disease. However, the outcomes of pancreatic cancer surveillance in high-risk individuals are not sorted out yet. In this review, we will address the identification of individuals at high risk for PDAC, discuss the objectives and targets of surveillance, outline how surveillance programs are organized, summarize the outcomes of high-risk individuals undergoing pancreatic cancer surveillance, and conclude with a future perspective on pancreatic cancer surveillance and novel developments.

Related collections

Most cited references 120

Record: found
Abstract: found
Article: found

Is Open Access

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Prashanth Rawla, Tagore Sunkara, Vinaya Gaduputi (2019)

Pancreatic cancer is the seventh leading cause of cancer-related deaths worldwide. However, its toll is higher in more developed countries. Reasons for vast differences in mortality rates of pancreatic cancer are not completely clear yet, but it may be due to lack of appropriate diagnosis, treatment and cataloging of cancer cases. Because patients seldom exhibit symptoms until an advanced stage of the disease, pancreatic cancer remains one of the most lethal malignant neoplasms that caused 432,242 new deaths in 2018 (GLOBOCAN 2018 estimates). Globally, 458,918 new cases of pancreatic cancer have been reported in 2018, and 355,317 new cases are estimated to occur until 2040. Despite advancements in the detection and management of pancreatic cancer, the 5-year survival rate still stands at 9% only. To date, the causes of pancreatic carcinoma are still insufficiently known, although certain risk factors have been identified, such as tobacco smoking, diabetes mellitus, obesity, dietary factors, alcohol abuse, age, ethnicity, family history and genetic factors, Helicobacter pylori infection, non-O blood group and chronic pancreatitis. In general population, screening of large groups is not considered useful to detect the disease at its early stage, although newer techniques and the screening of tightly targeted groups (especially of those with family history), are being evaluated. Primary prevention is considered of utmost importance. Up-to-date statistics on pancreatic cancer occurrence and outcome along with a better understanding of the etiology and identifying the causative risk factors are essential for the primary prevention of this disease.

0 comments Cited 849 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Whole genomes redefine the mutational landscape of pancreatic cancer.

Nicola Waddell, Marina Pajic, Ann-Marie Patch … (2015)

Pancreatic cancer remains one of the most lethal of malignancies and a major health burden. We performed whole-genome sequencing and copy number variation (CNV) analysis of 100 pancreatic ductal adenocarcinomas (PDACs). Chromosomal rearrangements leading to gene disruption were prevalent, affecting genes known to be important in pancreatic cancer (TP53, SMAD4, CDKN2A, ARID1A and ROBO2) and new candidate drivers of pancreatic carcinogenesis (KDM6A and PREX2). Patterns of structural variation (variation in chromosomal structure) classified PDACs into 4 subtypes with potential clinical utility: the subtypes were termed stable, locally rearranged, scattered and unstable. A significant proportion harboured focal amplifications, many of which contained druggable oncogenes (ERBB2, MET, FGFR1, CDK6, PIK3R3 and PIK3CA), but at low individual patient prevalence. Genomic instability co-segregated with inactivation of DNA maintenance genes (BRCA1, BRCA2 or PALB2) and a mutational signature of DNA damage repair deficiency. Of 8 patients who received platinum therapy, 4 of 5 individuals with these measures of defective DNA maintenance responded.

0 comments Cited 566 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Is Open Access

European evidence-based guidelines on pancreatic cystic neoplasms

(2018)

Evidence-based guidelines on the management of pancreatic cystic neoplasms (PCN) are lacking. This guideline is a joint initiative of the European Study Group on Cystic Tumours of the Pancreas, United European Gastroenterology, European Pancreatic Club, European-African Hepato-Pancreato-Biliary Association, European Digestive Surgery, and the European Society of Gastrointestinal Endoscopy. It replaces the 2013 European consensus statement guidelines on PCN. European and non-European experts performed systematic reviews and used GRADE methodology to answer relevant clinical questions on nine topics (biomarkers, radiology, endoscopy, intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), serous cystic neoplasm, rare cysts, (neo)adjuvant treatment, and pathology). Recommendations include conservative management, relative and absolute indications for surgery. A conservative approach is recommended for asymptomatic MCN and IPMN measuring 5 mm, and MPD diameter >10 mm. Lifelong follow-up of IPMN is recommended in patients who are fit for surgery. The European evidence-based guidelines on PCN aim to improve the diagnosis and management of PCN.

0 comments Cited 351 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Contributors

Aleksander M. Bogdanski:

ORCID: http://orcid.org/0000-0001-8632-9277

A.M.Bogdanski@lumc.nl

Journal

Journal ID (nlm-ta): Fam Cancer

Journal ID (iso-abbrev): Fam Cancer

Title: Familial Cancer

Publisher: Springer Netherlands (Dordrecht )

ISSN (Print): 1389-9600

ISSN (Electronic): 1573-7292

Publication date (Electronic): 15 April 2024

Publication date PMC-release: 15 April 2024

Publication date (Print): 2024

Volume: 23

Issue: 3

Pages: 323-339

Affiliations

[1 ]Department of Gastroenterology and Hepatology, Leiden University Medical Center, ( https://ror.org/05xvt9f17) Albinusdreef 2, 2333 ZA Leiden, The Netherlands

[2 ]Department of Radiology, Leiden University Medical Center, ( https://ror.org/05xvt9f17) Leiden, The Netherlands

[3 ]Department of Surgery, Leiden University Medical Center, ( https://ror.org/05xvt9f17) Leiden, The Netherlands

[4 ]Department of Gastrointestinal Oncology, Netherlands Cancer Institute, ( https://ror.org/03xqtf034) Amsterdam, The Netherlands

Author information

Aleksander M. Bogdanski http://orcid.org/0000-0001-8632-9277

Article

Publisher ID: 368

DOI: 10.1007/s10689-024-00368-1

PMC ID: 11255004

PubMed ID: 38619782

SO-VID: 140282e7-e536-4ed6-a758-675256c5ded4

License:

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

History

Date received : 5 January 2024

Date accepted : 24 February 2024

Custom metadata

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: pancreatic ductal adenocarcinoma,pancreatic cancer surveillance,high-risk individuals,early detection

Data availability:

ScienceOpen disciplines: Oncology & Radiotherapy

Keywords: pancreatic ductal adenocarcinoma, pancreatic cancer surveillance, high-risk individuals, early detection

Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer

Read this article at

Abstract

Related collections

Karger: Oncology

Most cited references 120

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Whole genomes redefine the mutational landscape of pancreatic cancer.

European evidence-based guidelines on pancreatic cystic neoplasms

Author and article information

Contributors

Journal

Affiliations

Author information

Article

History

Categories

Custom metadata

Comments

Comment on this article

Similar content 347

Cited by 2

Most referenced authors 1,806